PREVALENCE OF ANTI-HBC IN HBSAG-NEGATIVE POPULATION
SCREENING OF PATIENTS WITH UNSPECIFIED ACUTE HEPATITIS AND REVIEW OF THE LITERATURE
Keywords:HBV, anti-HBc, acute hepatitis
Background. Among the various serological markers employed in the hepatitis B virus (HBV) differential laboratory diagnosis, serum HBsAg is considered the most reliable. In order to characterise the HBV infection, another important diagnostic marker is employed – the HBc antibody (anti-HBc). There are three categories of anti-HBc-positive individuals: patients with HBV immunity, patients with chronic HBV and individuals with the so-called isolated anti-HBc pattern. The current study aimed to evaluate the presence of anti-HBc in patients negative for HBsAg whose clinical diagnosis was acute viral hepatitis.
Material and methods. A total of 88 specimens were examined, of which 75 sera were from prospective patients diagnosed with acute viral hepatitis, and 13 sera from breast milk donors. Antibodies against the hepatitis B core antigen were detected by enzyme-linked immunosorbent assay (ELISA).
Results. Twenty-eight (32%) of all tested samples were positive for anti-HBc. Nineteen samples belonged to male and 9 to female patients. One positive sample was from a breast milk donor. Two age groups, namely 46-55 years and 56-65 years, demonstrated the highest rate of anti-HBc positivity. Among the other age groups positivity rates varied from 15% to 36%. The results demonstrated a linear trend of increasing anti-HBc prevalence with increasing age.
Conclusions. Considering the highest rate of anti-HBc positivity being demonstrated in the age range 46-65 years, it could be assumed that a sufficient number of risk factors accumulate over time resulting in greater population susceptibility to HBV infection.
2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-1555.
3. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015; 5(5):a021410.
4. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003; 39:S64–S69.
5. Teoharov P, Kevorkyan A. Principal hepatotropic viruses in Bulgaria: characteristics, diagnosis, incidence, specific prophylaxis, Sofia, 2014. [in Bulgarian]
6. Kurchatova A, Vladimirova N, Minkova A, Kamenov G, Stoitsova S, Parmakova K. Acute infectious diseases in Bulgaria in 2017 (Key Epidemiological Indicators). https://www.ncipd.org/index.php?option=com_docman&view=list&slug=analysis-2017&Itemid=1127&lang=bg
7. Ministry of Health 2006, Ordinance No. 21 on the Procedure for Registration, Reporting and Control of Infectious Diseases, http://www.mh.government.bg/media/filer_public/2015/04/17/naredba-21-ot-2005g-spisak-zarazni-bolesti-red-registratsia.pdf
8. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B Virus Infection: Epidemiology and Vaccination. Epidemiol Rev. 2006; 28:112-125.
9. Elgouhari H, Tamimi T, Carey W. Hepatitis B virus infection: Understanding its epidemiology, course, and diagnosis. Clev Clin J Med. 2008; 75(12):881-889.
10. Horvat RT. Diagnostic and Clinical Relevance of HBV Mutations. Lab Med. 2011; 42(8):488-496.
11. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018; 67(No. RR-1):1-31.
12. Japhet MO, Adesina OA, Donbraye E, Adewumi MO. Hepatitis B core IgM antibody (anti-HBcIgM) among hepatitis B surface antigen (HBsAg) negative blood donors in Nigeria. Virol J. 2011; 8:513.
13. Karra VK, et al. Clinical Significance of Quantitative HBsAg Titres and its Correlation with HBV DNA Levels in the Natural History of Hepatitis B Virus Infection. J Clin Exp Hepatol. 2016; 6(3):209-215.
14. Dufour DR. Hepatitis B Surface Antigen (HBsAg) Assays—Are They Good Enough for Their Current Uses? Clin Chem. 2006; 52(8):1457-1459.
15. Trepo CG, et al. Hepatitis B antigen (HBsAg) and/or antibodies (anti-HBs and anti-HBc) in fulminant hepatitis: pathogenic and prognostic significance. Gut. 1976; 17(1):10-13.
16. Shimizu M, Ohyama M, Takahashi Y, et al. Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis. Gastroenterology. 1983; 84:604-610.
17. Lau GK. How do we handle the anti-HBc positive patient? (in highly endemic settings). Clin Liver Dis. 2015; 5:29-31.
18. Jain M, Chakravarti A, Kar P. Clinical significance of isolated anti-HBc positivity in cases of chronic liver disease in New Delhi, India. J Glob Infect Dis. 2009; 1(1):29-32.
19. Pondé RAA, Cardoso DDP, Ferro MO. The underlying mechanisms for the ‘anti-HBc alone’ serological profile. Arch Virol. 2010; 155:149-158.
20. Chang JJ, Mohtashemi N, Bhattacharya D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV/AIDS Rep. 2018; 15:172-181.
21. Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody—A Review of New Issues. Am J Gastroenterol. 2017; 112:1780-1788.
22. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013; 10:239.
23. Gessoni G, Beggio S, Barin P, et al. Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination. Blood Transfus. 2014; 12(1):s63-s68.
24. Wedemeyer H, Cornberg M, Tegtmeyer B, Frank H, Tillmann HL and Manns MP. Isolated anti-HBV core phenotype in anti- HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect. 2004; 10:70-72.
25. Mushahwar IK, Dienstag JL, Polesky HF, McGrath LC, Decker RH, Overby LR. Interpretation of Various Serological Profiles of Hepatitis B Virus Infection. Am J Clin Pathol. 1981; 76:773-777.
26. Ayoub WS, Martin P, Bhamidimarri KR. Hepatitis B Virus Infection and Organ Transplantation. Gastroenterol Hepatol. 2018; 14(1):33-40.
- 2020-05-13 (2)
- 2020-05-12 (1)